Form 4: BeOne Medicines COO Sells Shares for Tax Withholding Following RSU Vesting

BeOne Medicines Ltd.'s President and COO, Xiaobin Wu, reported the sale of 1,934 American Depositary Shares (ADS) on June 6, 2025, to cover tax obligations related to the vesting of restricted share units.

Summary

• Xiaobin Wu, President and COO of BeOne Medicines Ltd. (ONC), filed a Form 4 reporting transactions on June 6, 2025.
• The filing details the sale of a total of 1,934 American Depositary Shares (ADS) across five separate transactions.
• These sales were executed at weighted average prices ranging from $250.735 to $255.7693 per ADS.
• The purpose of these sales was to satisfy mandatory tax withholding provisions associated with the vesting of a previously granted restricted share unit (RSU) award.
• Following these transactions, Mr. Wu directly holds 1,150,926 Ordinary Shares and 0 American Depositary Shares.
• Additionally, Mr. Wu's wife indirectly holds 4,000 American Depositary Shares.
• Each American Depositary Share represents 13 Ordinary Shares.
• The underlying RSU award vests 1/4th on each anniversary of June 5, 2024, contingent on continued service, with accelerated vesting possible upon certain termination events following a change in control.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While shares were sold, it was for a mandatory tax obligation related to the vesting of equity compensation, which is a positive event for the executive. It does not indicate a discretionary sale or a negative outlook on the company.

Positives

• The underlying event, the vesting of restricted share units, indicates a component of executive compensation being realized, which is generally a positive for the executive.
• The sale was for mandatory tax withholding, not a discretionary sale, which typically mitigates concerns about insider selling.

Future Outlook

The restricted share unit award, from which these shares vested, is structured to vest 1/4th on each anniversary of June 5, 2024, subject to the executive's continued service. There is also a provision for accelerated vesting under certain termination events following a change in control.

Management Comments

• The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, specifically a sale of shares to cover tax liabilities arising from the vesting of equity compensation. Such transactions are common across all industries for executives receiving restricted stock units or similar equity awards, and do not typically reflect a change in the company's strategic direction or broader industry trends.

Stakeholder Impact

• Shareholders: Minimal direct impact as the sale is for tax purposes and not a discretionary divestment, suggesting no change in management's long-term view.
• Employees: No direct impact mentioned, but the vesting of RSUs is a standard part of executive compensation packages.

Next Steps

• Future vesting of the remaining restricted share units on subsequent anniversaries of June 5, 2024, subject to continued service.

Key Dates

Keywords

BeOne Medicines, ONC, Form 4, Insider Trading, Share Sale, Executive Compensation, Restricted Share Units, Tax Withholding, American Depositary Shares